Treatment of complications of diabetes with substances reactive

Details Treatment of complications of diabetes with substances reactive Treatment of complications of diabetes with substances reactive

1994-03-22

1996-05-21

Parr, Margaret

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Binds specifically-identified oligosaccharide structure

4241301, 4241341, 4241451, 5303875, 53038825, A61K 39395, C07K 1618

Patent

active

055187200

ABSTRACT:
Methods of in vivo diagnosis and treatment for complications of diabetes are provided. Antibodies or other mimetic molecules which specifically bind to glycated albumin or its cellular receptor are administered to a human. Glycated albumin which retains a deoxyfructosyllysine moiety is found deposited at sites of diabetic tissue damage. Glycated albumin inhibits the growth of cells. Treatment with monoclonal anti-glycated albumin antibody reverses the growth inhibition caused by glycated albumin. In addition, glycated albumin stimulates the production of type IV collagen by kidney cells. Antibodies which bind to glycated albumin prevent the stimulation of type IV collagen production.

REFERENCES:
patent: 4797473 (1989-01-01), Tarsio et al.
patent: 5173422 (1992-12-01), Knowles et al.
Hud & Cohen Clincy Chimicaacta 185:157-164 (1989).
Joliffe Intern Rev. Immunol 10:241-50 (1993).
Castano et al. Ann Rev Immunol 8:647-79 (1990).
Sabbatini et al. Kidney Intl. 42:875-881 (1992).
Predescu et al. J Cell Biol 107: 1729-1738 (1988).
Witzum et al. PNAS 81: 3204-3208 (1984).
Mountain et al. Biotech Gen Eng Rev 10, pp. 1 10-13 (1992).
Merckmanual pp. 1106-1107 16th Ed. 1992.
Van Brunt Bioworld Financial Watch 3:1-9 (1995).
Waldmann Science 252: 1657-1662 (1991).
Dillman Annals Int. Med 111: 592-603 (1989).
Harris et al. Tibtech 11: 42-44 (1993).
The Green Sheet 1003; 42(28)2-3.
The Pink Sheet 1991; 43(35:T&G-10-11.
The Gray Sheet 1993; 19(23):I&W-8-I&W-9.
The Green Sheet 1993; 42(3):1.
The Pink Sheet, Nov. 2, 1987.
Hygeia Pharmaceuticals, Inc. Advertisement (1992).
Cambridge Antibody Technology Ltd. Advertisement.
Beck, et al., "Brief Report: Alleviation of Systematic Manifestations of Castleman's Disease by Monoclonal Anti-Interleukin-6 Antibody", The New England Journal of Medicine, 330(9):602-605 (1994).
The Pink Sheet 1994; 56(3):8-91.
Vuillez, et al., "Immunoscintigraphy Using .sup.111 In-Labeled F(ab')hd 2 Fragments of Anticarcinoembryonic Antigen Monoclonal Antibody for Detecting Recurrences of Medullary Thyroid Carcinoma", J. Clin. Endo. and Metabolism, 74(1):157-163 (1992).
Serafini, "Biocompatible MoAbs Detect, Stage Disease", Diagnostic Imaging, pp. 94-98, Jun. 1990.
Riechmann, et al., "Reshaping Human Antibodies for Therapy", Nature, 332:323-327 (1988).
Saragovi, et al., "Design and Synthesis of a Mimetic from an Antibody Complementarity-Determining Region", Science, 253:792-794 (1991).
Mayforth, et al., "Designer and Catalytic Antibodies", New England Journal of Medicine, 323(3):173-178 (1990).
Kaminski, et al., "Radioimmunotherapy of B-Cell Lymphoma with [.sup.131 I]Anti-B1 (Anti-CD20) Antibody", New England Journal of Medicine, 329:(7):459-465 (1993).
Steplewski, et al., "Biological Activity of Human-Mouse IgG1, IgG2 IgG3, IgG4 Chimeric Monoclonal Antibodies with Antitumor Specificity"Proc. Natl. Acad. Sci. USA, 85:4852-4856 (1988).
Sun, et al., "Chimeric Antibody with Human Constant Regions and Mouse Variable Regions Directed Against Carcinoma-Associated Antigen 17-1A", Proc. Natl. Acad. Sci. USA, 84:214-218 (1987).
Wolff, et al., "The Use of Digoxin-Specific Fab Fragments for Severe Digitals Intoxication in Children", New England Journal of Medicine, 326(26):1739-1744 (1992).
Press, et al., "Radiolabeled Antibody Therapy of B-cell Lymphoma with Autologous Bone Marrow Support", New England Journal of Medicine , 329(17):1219-1224 (1993).
Cohen, et al., "Production and Characterization of Monoclonal Antibodies Against Human Glycoalbumin", J. Immunol. Methods, 117:121-129 (1989).
Kelley, et al., "A Method for Localizing the Early Products of Nonenzymatic Glycosylation in Fixed Tissue," J. Investigative Dermatology, 93(3):327-331 (1989).
Michael, et al., "Incresaed Concentration of Albumin in Kidney Basement Membranes in Diabetes Mellitus", Diabetes, 30:843-846 (1981).
Shaklai, et al., "Nonenzymatic Glycosylation of Human Serum Albumin Alters Its Conformation and Function", J. Biol. Chem., 259(6):3812-3817.
Williams, et al., "Preferential transport of Non-Enzymatically Glucosylated Ferritin Across the Kidney Glomerulus", Kidney International, 28:146-152 (1985).
Brownlee, et al., "Covalent Attachment of Soluble Proteins by Nonenzymatically Glucosylated Collagen", J. Exp. Med., 158:1739-1744 (1983).
Vaughn, et al., "Diabetes, Autoimmunity, and Arteriosclerosis", Clin. Immun. and Immunpath., 52:414-420 (1989).
Brownlee, et al., "Nonenzymatic Glycosylation Products on Collagen Covalently Trap Low-Density Lipoprotein", Diabetes, 34:938-941 (1985).
Miller, et al., "Immunopathology of Renal Extracellular Membranes in Diabetes Mellitus", Diabetes, 25:(8):701-708 (1976).
Williams, et al., "Enhanced Vesicular Ingestion of Nonenzymatically Glycosylated Proteins by Capillary Endothelium", Microvascular Research, 28:311-321 (1984).
Williams et al., "Micropinocytic Ingestion of Glycosylated Albumin by Isolated Microvessels: Possible Role in Pathogenesis of Diabetic Microangiopathy", Proc. natl. Acad. Sci. USA, 78(4):2393-2397 (1981).
Smith, et al., "Premeability and Mechanism of Albumin, Cationized Albumin, and Glycosylated Albumin Transcellular Transport Across Monolayers of Cultured Bovine Brain Capillary Endothelial Cells", Pharm. Res., 6(6):466-473 (1989).
McVerry, et al., "Production of Psuedodiabetic Renal Glomerular Changes in Mice After Repeated Injections of Glucosylated Proteins,", The Lancet, 1(8171):738-740 (1980).
Aggarwal, et al., "Increased Uptak eof Glycated Albumin by Glomerular Mesangial and Epithelial Cells In Situ is Accompanied by Augmented Local Production of H.sub.2 O.sub.2 : Studies Utilizing Confocal Microscopy," Clin. Res., 40:179A (1992).

Affiliated with

Also associated with

Rating

Treatment of complications of diabetes with substances reactive does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of complications of diabetes with substances reactive , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of complications of diabetes with substances reactive will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2035986